Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the inclusion of its blood-based colorectal cancer screening product Shield in TIME’s annual list of the Best Inventions, which features 200 extraordinary innovations changing lives.

To compile this year's list, TIME solicited nominations from TIME editors and correspondents around the world, and through an online application process, paying special attention to growing fields—such as health care, AI, and green energy. TIME then evaluated each contender on a number of key factors, including originality, efficacy, ambition, and impact.

“We’re honored to be a part of this prestigious list of leading innovative products that are making a dramatic difference in how we live our lives today,” said AmirAli Talasaz, co-CEO and co-Founder of Guardant Health. “We created Guardant Health with the vision to detect and characterize cancer across the spectrum, and now we are able to do this with colorectal cancer at earlier stages with the launch of Shield. This has the opportunity to transform cancer detection and save millions of lives.”

Of the new list, TIME’s editors write: “The result is a list of 200 groundbreaking inventions (and 50 special mention inventions)—including the world's largest computer chip, a humanoid robot joining the workforce, and a bioluminescent houseplant—that are changing how we live, work, play, and think about what’s possible.”

Guardant recently reached several significant milestones, including announcing that it has achieved 500 peer-reviewed publications and more than 500,000 patient tests delivered. Shield was approved by the Food and Drug Administration in July 2024, and reimbursed by Medicare shortly thereafter.

See the full list here: time.com/best-inventions-2024

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn and X (Twitter).

View source version on businesswire.com: https://www.businesswire.com/news/home/20241030233321/en/